Novimmune et Sobi revoient leurs accords

Novimmune et Sobi revoient leurs accords

Swedish Orphan Biovitrum AB (publ)(Sobi™) (SOBI.ST) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded.

Sobi is exiting drug discovery and early research outside of hematology and immunology. The Swedish biopharma unveiled the news alongside the CHF 515 million ($518 million) acquisition of immunology R&D capabilities from Novimmune.

In the future, Sobi’s R&D group will be centered on two sites in Sweden and Switzerland—where Novimmune is based—from which it will oversee a pipeline of hematology and immunology assets. Sobi will divert the money saved by the cuts into these programs.

The revised deal sees Sobi buy IFNγ inhibitor emapalumab and associated assets outright. For CHF 515 million, most of which Sobi previously committed in the licensing deal, Sobi is acquiring the drug, staff involved in the clinical development of emapalumab, options on two immuno-oncology assets and a FDA priority review voucher it can either use or sell.

More

Leave a reply